Literature DB >> 28196281

Validation of data in the Medical Birth Registry of Norway on delivery after a previous cesarean section.

Sjur Lehmann1, Elham Baghestan2, Per Børdahl1,2, Marta Ebbing3,4, Lorentz Irgens4, Svein Rasmussen1,2.   

Abstract

INTRODUCTION: Trial of labor (TOL) is an option in most deliveries after a previous cesarean section (CS). The Medical Birth Registry of Norway (MBRN) has received compulsory notification of all deliveries in the country since 1967, including data that could identify TOL in epidemiologic research. The objective of this study was to validate MBRN data for identification of TOL deliveries after a previous cesarean section (CS).
MATERIAL AND METHODS: The MBRN provided a random national sample of 500 birth order two deliveries during 1989-2012 in women with a registered birth order one CS delivery. The reporting maternity units were asked to complete a questionnaire on data items in both deliveries, using hospital record data as the gold standard.
RESULTS: Completed questionnaires were returned for 477 women (95.5%) with data on both deliveries. An algorithm to identify TOL using MBRN data from the birth order two delivery had a positive predictive value of 93.2%, a negative predictive value of 93.5%, a sensitivity of 96.1%, and a specificity of 88.8%. Validity of MBRN data on mode and onset of delivery, CS subtype, and planned mode of delivery is also reported.
CONCLUSIONS: MBRN data on planned and actual mode of delivery, CS subtype, and the algorithm to identify TOL in deliveries after a previous CS had satisfactory quality for a registry-based study of TOL.
© 2017 Nordic Federation of Societies of Obstetrics and Gynecology.

Entities:  

Keywords:  Norway; cesarean section; delivery; obstetric; pregnancy; registries; sensitivity and specificity; trial of labor

Mesh:

Year:  2017        PMID: 28196281     DOI: 10.1111/aogs.13115

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  6 in total

1.  The provision of epidural analgesia during labor according to maternal birthplace: a Norwegian register study.

Authors:  Åsa Henning Waldum; Anne Flem Jacobsen; Mirjam Lukasse; Anne Cathrine Staff; Ragnhild Sørum Falk; Siri Vangen; Ingvil Krarup Sørbye
Journal:  BMC Pregnancy Childbirth       Date:  2020-05-26       Impact factor: 3.007

2.  Low risk pregnancies after a cesarean section: Determinants of trial of labor and its failure.

Authors:  Sjur Lehmann; Elham Baghestan; Per E Børdahl; Lorentz M Irgens; Svein Rasmussen
Journal:  PLoS One       Date:  2020-01-13       Impact factor: 3.240

3.  How common is substandard obstetric care in adverse events of birth asphyxia, shoulder dystocia and postpartum hemorrhage? Findings from an external inspection of Norwegian maternity units.

Authors:  Lars T Johansen; Geir Sverre Braut; Ganesh Acharya; Jan Fredrik Andresen; Pål Øian
Journal:  Acta Obstet Gynecol Scand       Date:  2020-08-05       Impact factor: 3.636

4.  Recurrence of postpartum hemorrhage, maternal and paternal contribution, and the effect of offspring birthweight and sex: a population-based cohort study.

Authors:  Lorentz Erland Linde; Cathrine Ebbing; Dag Moster; Jörg Kessler; Elham Baghestan; Mika Gissler; Svein Rasmussen
Journal:  Arch Gynecol Obstet       Date:  2022-01-09       Impact factor: 2.493

5.  Association between Maternal Origin, Pre-Pregnancy Body Mass Index and Caesarean Section: A Nation-Wide Registry Study.

Authors:  Fatou Jatta; Johanne Sundby; Siri Vangen; Benedikte Victoria Lindskog; Ingvil Krarup Sørbye; Katrine Mari Owe
Journal:  Int J Environ Res Public Health       Date:  2021-06-01       Impact factor: 3.390

6.  Does caesarean delivery in the first pregnancy increase the risk for adverse outcome in the second? A registry-based cohort study on first and second singleton births in Norway.

Authors:  Solveig Bjellmo; Guro L Andersen; Sissel Hjelle; Kari Klungsøyr; Lone Krebs; Stian Lydersen; Pål Richard Romundstad; Torstein Vik
Journal:  BMJ Open       Date:  2020-08-23       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.